Cargando…

A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer

Triple negative breast cancers (TNBC) remain a major medical challenge due to poor prognosis and limited treatment options. Mesothelin is a glycosyl-phosphatidyl inositol-linked membrane protein with restricted normal expression and high level expression in a large proportion of TNBC, thus qualifyin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Del Bano, Joanie, Florès-Florès, Rémy, Josselin, Emmanuelle, Goubard, Armelle, Ganier, Laetitia, Castellano, Rémy, Chames, Patrick, Baty, Daniel, Kerfelec, Brigitte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636429/ https://www.ncbi.nlm.nih.gov/pubmed/31354732 http://dx.doi.org/10.3389/fimmu.2019.01593

Ejemplares similares

Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?
por: Del Bano, Joanie, et al.
Publicado: (2015)

Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies
por: Benloucif, Abdennour, et al.
Publicado: (2023)

A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy
por: Turini, Marc, et al.
Publicado: (2014)

Therapeutic Antibodies for the Treatment of Pancreatic Cancer
por: Chames, Patrick, et al.
Publicado: (2010)

Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response
por: Raynaud, Adeline, et al.
Publicado: (2020)

Vitamin D Controls Tumor Growth and CD8+ T Cell Infiltration in Breast Cancer
por: Karkeni, Esma, et al.
Publicado: (2019)

A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors
por: Yoon, Aerin, et al.
Publicado: (2020)

Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies
por: Gopalakrishnapillai, Anilkumar, et al.
Publicado: (2021)

Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors
por: Hatterer, Eric, et al.
Publicado: (2020)

Modeling Heterogeneity of Triple‐Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug Resistance
por: Lamballe, Fabienne, et al.
Publicado: (2020)

Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity
por: Bernard, Pierre-Louis, et al.
Publicado: (2022)

Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors
por: Luke, Jason J, et al.
Publicado: (2021)

Therapeutic Targeting of c-Myc in T-Cell Acute Lymphoblastic Leukemia (T-ALL)
por: Loosveld, Marie, et al.
Publicado: (2014)

Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival
por: Tozbikian, Gary, et al.
Publicado: (2014)

Mesothelin-Specific Immune Responses and Targeted Immunotherapy for Mesothelin-Expressing Tumors
por: Einama, Takahiro, et al.
Publicado: (2017)

Association between mesothelin expression and survival outcomes in patients with triple-negative breast cancer: a protocol for a systematic review
por: Wang, Mei, et al.
Publicado: (2016)

Near infrared photoimmunotherapy with an anti-mesothelin antibody
por: Nagaya, Tadanobu, et al.
Publicado: (2016)

Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer
por: Liu, Huicheng, et al.
Publicado: (2021)

Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors
por: Zhao, Xiao-Yan, et al.
Publicado: (2016)

Favorable therapeutic response after anti-Mesothelin antibody–drug conjugate treatment requires high expression of Mesothelin in tumor cells
por: Lazzerini, Lea, et al.
Publicado: (2020)

Targeting mesothelin in ovarian cancer
por: Ghafoor, Azam, et al.
Publicado: (2018)

Liver myofibroblasts of murine origins express mesothelin: Identification of novel rat mesothelin splice variants*
por: Fausther, Michel, et al.
Publicado: (2017)

Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo
por: Ye, Lin, et al.
Publicado: (2019)

Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin
por: Liu, Xiufen, et al.
Publicado: (2022)

An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin
por: Snell, Daniel, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
por: Thomas, Remy, et al.
Publicado: (2021)

Establishment of a mouse xenograft model of metastatic adrenocortical carcinoma
por: Morin, Aurélie, et al.
Publicado: (2017)

Eradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with optimized anti-mesothelin antibody–drug conjugates from synthetic antibody libraries
por: Hsu, Hung-Ju, et al.
Publicado: (2021)

The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors
por: Yu, Yi, et al.
Publicado: (2011)

Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment
por: Zhang, Xianyu, et al.
Publicado: (2022)

Structures of Cancer Antigen Mesothelin and Its Complexes with Therapeutic Antibodies
por: Zhan, Jingyu, et al.
Publicado: (2023)

Modulating Mesothelin Shedding to Improve Therapy
por: Zhang, Yujian, et al.
Publicado: (2012)

Mesothelin as a biomarker for targeted therapy
por: Lv, Jiang, et al.
Publicado: (2019)

Mesothelin-specific T cell cytotoxicity against triple negative breast cancer is enhanced by 40s ribosomal protein subunit 3-treated self-differentiated dendritic cells
por: Jirapongwattana, Niphat, et al.
Publicado: (2022)

PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer
por: Al-Khadairi, Ghaneya, et al.
Publicado: (2019)

A Novel Bispecific Antibody Targeting EGFR and VEGFR2 Is Effective against Triple Negative Breast Cancer via Multiple Mechanisms of Action
por: Mohan, Nishant, et al.
Publicado: (2021)

Bispecific antibodies and their applications
por: Fan, Gaowei, et al.
Publicado: (2015)

The making of bispecific antibodies
por: Brinkmann, Ulrich, et al.
Publicado: (2017)

The Impact of Mesothelin in the Ovarian Cancer Tumor Microenvironment
por: Hilliard, Tyvette S.
Publicado: (2018)

Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors
por: Hagerty, Brendan L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2fo01qk6da5153ovr7nmsge61r